Aims: To report the beneficial effect of intravitreal bevacizumab (Avastin) injection in patients with acute central serous chorioretinopathy. Methods: Ten eyes of 10 patients with acute central serous chorioretinopathy received an intravitreal bevacizumab (1.25 mg/0.05 ml) injection. At baseline and follow-up visits patients had best corrected visual acuity (BCVA), IOP assessment, dilated fundus examination and OCT imaging. Main outcome measures were the resolution of neurosensory detachment, improvement in visual symptoms and visual acuity. Results: All patients showed resolution of neurosensory detachment promptly, and improvement in visual acuity and symptoms within 1 month. In 1 case, fluorescein leakage resolved and neurosensory detachment nearly resolved at 2 weeks after treatment. At 6 months the mean BCVA (LogMAR) had improved from 0.32 to 0.04, which was statistically significant (p = 0.007, Wilcoxon signed ranks test). No recurrence was observed during a 6-month follow-up. Conclusions: Intravitreal bevacizumab injection for acute central serous chorioretinopathy may result in prompt resolution of neurosensory detachment and reduction of angiographic leakage. These short-term results suggest that intravitreal bevacizumab injection may constitute a promising therapeutic option in acute central serous chorioretinopathy.

Keywords:
Central serous chorioretinopathy, Intravitreal bevacizumab (Avastin)
1.
Hayashi K, Hasegawa Y, Tokoro T: Indocyanine green angiography of central serous chorioretinopathy. Int Ophthalmol 1986;9:37–41.
2.
Prünte C: Indocyanine green angiography findings in central serous chorioretinopathy. Int Ophthalmol 1995;19:77–82.
3.
Prünte C, Flammer J: Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 1996;121:26–34.
4.
Stanga PE, Lim JI, Hamilton P: Indocyanine green angiography in chorioretinal diseases: indications and interpretation: an evidence-based update. Ophthalmology 2003;110:15–21.
5.
Piccolino FC, Borgia L: Central serous chorioretinopathy and indocyanine green angiography. Retina 1994;14:231–242.
6.
Piccolino FC, Borgia L, Zinicola E, Zingirian M: Indocyanine green angiographic findings in central serous chorioretinopathy. Eye 1995;9:324–332.
7.
Slakter JS, Yannuzzi LA, Guyer DR, Sorenson JA, Orlock DA: Indocyanine-green angiography. Curr Opin Ophthalmol 1995;6:25–32.
8.
Spaide RF, Hall L, Haas A, Campeas L, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA: Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 1996;16:203–213.
9.
Yuzawa M, Kawamura A, Yamaguchi C, Shouda M, Shimoji M, Matsui M: Indocyanine green videoangiographic findings in detachment of the retinal pigment epithelium. Ophthalmology 1995;102:622–629.
10.
Guyer DR, Yannuzzi LA, Slakter JS, et al: Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 1994;112:1057–1062.
11.
Menchini U, Virgili G, Lanzetta P, Ferrari E: Indocyanine green angiography in central serous chorioretinopathy. Int Ophthalmol1997;21:57–69.
12.
Uyama M, Matsunaga H, Matsubara T, Fukushima I, Takahashi K, Nishimura T: Indocyanine green angiography and pathophysiology of multifocal posterior pigment epitheliopathy. Retina 1999;19:12–21.
13.
Constantinides G: Relation between retinal pigment epithelial detachment and dye leakage in central serous retinopathy. J Fr Ophtalmol 2000;23:649–654.
14.
Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa DL, Huang SJ, Klancnik JM Jr, Aizman A: Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003;23:288–289.
15.
Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Ho A, Orlock D: Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 1994;112:1057–1062.
16.
Iida T, Hagimura N, Otani T, Ikeda F, Muraoka K: Choroidal vascular lesions in serous retinal detachment viewed with indocyanine green angiography. Nippon Ganka Gakkai Zasshi 1996;100:817–824.
17.
Weis SM, Cheresh DA: Pathophysiological consequences of VEGF-induced vascular permeability. Nature 2005;437:497–504.
18.
Niegel MF, Schrage NF, Christmann S, Degenring RF: Intravitreal bevacizumab for chronic central serous chorioretinopathy (in German). Ophthalmologe 2008;105:943–945.
19.
Wang MS, Sander B, Larsen M: Retinal atrophy in idiopathic central serous chorioretinopathy. Am J Ophthalmol 2002;133:787–793.
20.
Fuhrmeister H: A long-term study of morphological and functional developments after central serous chorioretinitis. Klin Monatsbl Augenheilkd 1983;182:549–551.
21.
Wang M, Sander B, la Cour M, Larsen M: Clinical characteristics of subretinal deposits in central serous chorioretinopathy. Acta Ophthalmol Scand 2005;83:691–696.
22.
Ober MD, Yannuzzi LA, Do DV, et al: Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology 2005;112:2088–2094.
23.
Pikkel J, Beiran I, Ophir A, Miler B: Acetazolamide for central serous retinopathy. Ophthalmology 2002;109:1723–1725.
24.
Burumcek E, Mudun A, Karacorlu S, et al: Laser photocoagulation for persistent central serous retinopathy: results of long-term follow-up. Ophthalmology 1997;104:616–622.
25.
Canakis C, Conway MD, Livir-Rallatos C, et al: Ocular photodynamic therapy in choroidal neovascularization complicating idiopathic central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging 2004;35:168–171.
26.
Canakis C, Livir-Rallatos C, Panayiotis Z, et al: Ocular photodynamic therapy for serous macular detachment in the diffuse retinal pigment epitheliopathy variant of idiopathic central serous chorioretinopathy. Am J Ophthalmol 2003;136:750–752.
27.
Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM: Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003;23:752–763.
28.
Valmaggia C, Niederberger H: Photodynamic therapy in the treatment of chronic central serous chorioretinopathy. Klin Monatsbl Augenheilkd 2006;223:372–375.
29.
Chan WM, Lam DS, Lai TY, et al: Treatment of choroidal neovascularization in central serous chorioretinopathy by photodynamic therapy with verteporfin. Am J Ophthalmol 2003;136:836–845.
30.
Yannuzzi LA, Slakter JS, Gross NE, et al: Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003;23:288–298.
31.
Penha FM, Aggio FB, Bonomo PP: Severe retinal thermal injury after indocyanine green-mediated photothrombosis for central serous chorioretinopathy. Am J Ophthalmol 2007;143:887–889.
32.
Kanyange ML, De Laey JJ: Long-term follow-up of central serous chorioretinopathy (CSCR). Bull Soc Belge Ophtalmol 2002;284:39–44.
33.
Mennel S, Peter S, Meyer CH, et al: Effect of photodynamic therapy on the function of the outer blood-retinal barrier in an in vitro model. Graefes Arch Clin Exp Ophthalmol 2006;244:1015–1021.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.